The group of Bluestone is currently testing the safety of ex vivo expanded polyclonal CD4+CD25hiCD127low/− Tregs in a phase-I clinical trial (NCT01210664) in which increasing doses of Tregs will be injected in recent onset adult T1D patients (63). This evidence concerns the gene CD4 and type 1 diabetes mellitus.